NCT06843044招募中4 期
An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Evaluate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 250
- 试验地点
- 6
- 主要终点
- The proportion of patients with a significant reduction in anxiety levels (by 50% or more) on Hamilton Anxiety Rating Scale (HARS) compared to baseline on Day 29 ± 1 (Visit 3)
研究概览
简要总结
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females aged 18 to 70 years;
- •Written informed consent form in accordance with current legislation;
- •Patients with anxiety and established diagnoses based on ICD-10 criteria: neurasthenia (F48.0) or adjustment disorder (F43.2);
- •Anxiety severity on the HARS scale of 18-24 points;
- •Assessment of the severity of suicidal thoughts using the Columbia scale <3 points;
- •Severity of asthenia on the Multidimensional Fatigue Inventory Scale (MFI-20) greater than 50 points;
- •Total score on the Hamilton Depression Rating Scale (HAMD-17) < 6;
- •Score on the CGI-s scale of at least 4 points;
- •Negative pregnancy test for women of childbearing potential;
- •Agreement to use effective contraceptive methods throughout the study and for 30 days after its completion (for women of childbearing potential and men);
- •Ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of health-related information), and comply with the procedures outlined in the study protocol.
- •Non-inclusion Criteria:
- •Known intolerance to the active and/or excipient substances contained in the study drugs;
- •Known lactase deficiency, lactose intolerance, glucose-galactose malabsorption, or galactose intolerance;
- •Patients requiring prohibited concomitant therapy within this study (MAO inhibitors, antidepressants, neuroleptics, anxiolytics and sedatives (including herbal), hypnotics when used on a regular basis), or who have taken these medications within the last month;
- •Established or suspected alcohol/narcotic substance use at the time of screening or randomization, and/or a history of alcohol, narcotic, or drug dependence;
- •Presence of oncological diseases, including in history (except for cured tumors with stable remission for more than 5 years);
- •Tuberculosis, including in history;
- •Presence of HIV, chronic viral hepatitis B/C, syphilis (including past history), or a positive test for HIV, hepatitis B/C, or syphilis at screening;
- •Patients with a diagnosis of other anxiety disorders (F41) established based on ICD-10 criteria;
- •Schizophrenia, schizoaffective disorders, affective disorders, and panic disorders;
- •Acute psychosis (endogenous-processual, organic, or somatogenic), including in history;
- •Organic lesions of the central nervous system of traumatic and alcoholic origin;
- •Post-encephalitic syndrome;
- •History of brain tumors (including past diagnoses);
- •Degenerative diseases of the central nervous system (CNS), particularly multiple sclerosis;
- •History of depression (including past episodes);
- •Suicide attempts in history;
- •Generalized anxiety disorder, including in history;
- •History of epilepsy and seizures (including past episodes);
- •Decompensated diabetes mellitus;
- •Established diagnosis of chronic kidney disease stage 3A and above, or estimated glomerular filtration rate (eGFR) calculated by the Cockcroft-Gault formula ≤ 59 ml/min/1.73 m²;
- •Established diagnosis of liver failure of any severity, or elevated levels of ALT, AST or total bilirubin >3 times the upper limit of normal according to laboratory standards;
- •History of major surgical interventions within six months prior to screening;
- •Chronic heart failure III-IV functional class according to the New York Heart Association (NYHA) classification;
- •Severe, decompensated, or unstable diseases (any diseases or conditions that poses a life-threatening risk to the patient, worsens the patient's prognosis, or makes participation in the clinical study impossible);
- •Pregnant women, breastfeeding women, or women planning to become pregnant during the study or within 30 days after participation ends;
- •Refusal by the patient to use permitted methods of contraception or to completely abstain from sexual contact throughout the entire period of participation in the study starting from Visit 0 and for 30 days after completion of participation;
- •Current participation or planned participation by the patient in psychological or psychotherapeutic activities aimed at treating anxiety disorder during the clinical trial period;
- •Participation in any other clinical trial within 90 days prior to the start of the screening period;
- •Lack of patient cooperation;
- •Other reasons, at the investigator's discretion, that may hinder the patient's participation in the study or pose unjustified risk to the patient.
排除标准
- •The patient's decision to withdraw from the study (revocation of informed consent);
- •Each patient has the right to discontinue participation in the study at any time without explanation. Withdrawal from the study will not affect the medical care provided to the patient in the future;
- •The investigator's decision that the patient needs to be excluded in the best interest of the patient;
- •The patient refuses to cooperate with the investigator or is non-compliant;
- •Emergence of reasons/situations during the study that threaten the patient's safety (e.g., hypersensitivity reactions, serious adverse events, etc.);
- •Inclusion of a patient in the study that does not meet the inclusion/exclusion criteria, including cases of deviation from normal values in laboratory test results obtained at Visit 0;
- •Significant violation of the treatment regimen.
- •A significant violation is considered:
- •Missing doses of the study drugs for 2 consecutive days or more, or
- •Taking a total number of tablets < 80% or > 120% of the full course (the full course for Ranquilon is 168 tablets, and for Afobazole, it is 84 tablets).
- •Positive pregnancy test;
- •Confirmed diagnosis of COVID-19;
- •Emergence of other reasons during the study that prevent its conduct according to the protocol;
- •Patient death;
- •Sponsor-initiated study termination;
- •Termination of the study by the Investigator;
- •Termination of the study by regulatory authorities.
研究组 & 干预措施
Ranquilon, 6 mg/day
Experimental
Ranquilon, 1 mg tablets, at a dosage of 6 mg/day for 28 days
干预措施: Ranquilon (Drug)
Afobazole, 30 mg/day
Active Comparator
Afobazole, 10 mg tablets, at a dosage of 30 mg/day for 28 days
干预措施: Afobazole (Drug)
结局指标
主要结局
The proportion of patients with a significant reduction in anxiety levels (by 50% or more) on Hamilton Anxiety Rating Scale (HARS) compared to baseline on Day 29 ± 1 (Visit 3)
时间窗: Day 29 ± 1 (Visit 3)
HARS scale includes 14 items, each of which is rated on the Likken scale (from 0 points as absence of the symptom to 4 points as the worst possible symptom). Of these, 13 items relate to the manifestation of anxiety in daily life, 14th item relate to the manifestation of anxiety during examinations.
次要结局
- Change in the severity of the patient's condition on the Clinical Global Impression (CGI-s) scale by Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Change in anxiety levels according to the Hamilton Anxiety Rating Scale (HARS) scale on Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Proportion of patients with a reduction in anxiety levels on the Hamilton Anxiety Rating Scale (HARS) scale to 17 points or less on Day 29 ± 1 (Visit 3)(Day 29 ± 1 (Visit 3))
- Proportion of patients with a score of 2 points or less on the Clinical Global Impression (CGI-s) scale as assessed by the physician (healthy or borderline disorder) on Day 29 ± 1 (Visit 3)(Day 29 ± 1 (Visit 3))
- Change in the total score on the Multidimensional Fatigue Inventory (MFI-20) on Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Proportion of patients with a reduction in total score on the Multidimensional Fatigue Inventory (MFI-20) by 25% on Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Proportion of patients with a reduction in total score on the Multidimensional Fatigue Inventory (MFI-20) by 50% on Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Proportion of patients with a total score on the Multidimensional Fatigue Inventory (MFI-20) reduced to 30 points or less on Day 29 ± 1 (Visit 3)(Day 29 ± 1 (Visit 3))
- Absolute value of the patient's self-assessment of their subjective condition for all individual items on the Multidimensional Fatigue Inventory (MFI-20) scale by Day 29 ± 1 (Visit 3)(Day 29 ± 1 (Visit 3))
- Change in total score on the Columbia-Suicide Severity Rating Scale (C-SSRS) by Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Change in total score on the Emotional Eating Questionnaire by Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Change in total score on the Psychological Stress Measure (PSM-25) by Day 29 ± 1 (Visit 3) compared to baseline(Day 29 ± 1 (Visit 3))
- Safety and Tolerability: adverse event (AE) rate(From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 43 ± 1 for each participant)
- Safety and Tolerability: AEs associated with the study drug(From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 43 ± 1 for each participant)
- Safety and Tolerability: vital signs - systolic blood pressure (SBP)(Screening, day 1, day 29 ± 1, day 43 ± 1)
- Safety and Tolerability: vital signs - diastolic blood pressure (DBP)(Screening, day 1, day 29 ± 1, day 43 ± 1)
- Safety and Tolerability: treatment discontinuation(From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 43 ± 1 for each participant)
- Safety and Tolerability: vital signs - respiratory rate (RR)(Screening, day 1, day 29 ± 1, day 43 ± 1)
- Safety and Tolerability: vital signs - heart rate (HR)(Screening, day 1, day 29 ± 1, day 43 ± 1)
- Safety and Tolerability: vital signs - body temperature(Screening, day 1, day 29 ± 1, day 43 ± 1)
- Safety and Tolerability: concomitant treatment(From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 43 ± 1 for each participant)
- Safety and Tolerability: clinical blood test - hemoglobin(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - hematocrit(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - red blood cell count(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - platelet count(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - leukocyte count(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - myelocytes(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - band neutrophils(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - segmented neutrophils(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - basophils(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - monocytes(Screening, day 29 ± 1)
- Safety and Tolerability: clinical blood test - lymphocytes(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - specific gravity(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - color(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - transparency(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - pH(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - protein(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - glucose(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - red blood cells(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - white blood cells(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - epithelial cells(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - ketone bodies(Screening, day 29 ± 1)
- Safety and Tolerability: urinalysis - urobilinogen(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - glucose(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - protein(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - cholesterol(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - bilirubin(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - creatinine(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - alkaline phosphatase(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - alanine transaminase(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - aspartate transaminase(Screening, day 29 ± 1)
- Safety and Tolerability: blood chemistry - urea(Screening, day 29 ± 1)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Study Evaluating Safety and Efficacy of Ropanicant in MDD PatientsMajor Depressive DisorderNCT06126497Suven Life Sciences Limited41
终止
3 期
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson DiseaseNCT05047523Alexion Pharmaceuticals, Inc.40
已完成
1 期
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male SubjectsHealthyNCT02071381Daewon Pharmaceutical Co., Ltd.
已完成
3 期
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) PatientsPulmonary EmbolismNCT01516814Bayer40
已完成
1 期
Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol InjectionsOpioid-use DisorderNCT04828694BioCorRx Inc24